VIDAC PHARMA HOLDING PLC

Registered in England and Wales • Company number 13479728

FORM OF PROXY — ANNUAL GENERAL MEETING 2026

30 September 2026 at 9.30 am CEST / 10.30 am Israel time

Return by 9.00 am CEST / 10.00 am Israel time on Monday, 28 September 2026 to kronik@companiessecretary.com (subject: PROXY).

Shareholder name(s):

Registered address:

Shareholder reference (if known): Number of shares:

I/We, being a member/members of the Company, appoint the Chair of the meeting OR the person named below as my/our proxy to attend, speak and vote on my/our behalf at the AGM and any adjournment, as directed below. Leave the proxy name blank to appoint the Chair.

Alternative proxy name:

Shares covered by this appointment: Multiple proxy appointment: Yes / No

Mark one box with an X for each resolution. The descriptions below are summaries; the full resolutions are set out in the accompanying Notice. Resolutions 1–9 are ordinary; resolutions 10–11 are special.

No.	Resolution	For	Against	Withheld
1	Reappoint Dr Max Herzberg as a Director.
2	Reappoint Yochai Richter as a Director.
3	Reappoint Dr Christian Policard as a Director.
4	Reappoint Joseph Tenne as a Director.
5	Receive the 2025 annual report, audited financial statements and related reports.
6	Reappoint MHA Audit Services LLP as auditor until the conclusion of the next accounts meeting.
7	Authorise the Directors to determine the auditor’s remuneration.
8	Authorise allotment of shares and grant of subscription or conversion rights up to £10,694,620 nominal value, on the terms in the Notice.
9	Approve the strategy to conclude a licence agreement with Eutopos Pharma, initially in Europe, with final territory to be agreed.
10	Disapply statutory pre-emption rights on the terms in the Notice: up to £5,000,000 nominal value for specified allotments/rights and £5,694,620 for options.(Special)
11	Authorise capitalisation of reserves/share premium up to £5,000,000 to pay up shares, on the terms in the Notice.(Special)

Signature: Date:

Signatory name and capacity (if applicable):

NOTES TO THE FORM OF PROXY

Appointment and shares. A proxy need not be a shareholder. You may appoint more than one proxy, provided each is appointed for different shares. Complete a separate form for each proxy and state the number of shares covered. If the shares field is left blank, this appointment covers all shares registered in your name, subject to any other valid appointment.

Voting instructions. Mark only one voting box for each resolution. A vote withheld is not a vote in law and will not be counted in calculating votes for or against a resolution. If no instruction is given, the proxy may vote or abstain at their discretion. The proxy may also exercise discretion on other business properly put before the meeting.

Submission. Send a scanned copy of the completed and signed form by email to kronik@companiessecretary.com with “PROXY” in the subject line. It must be received no later than 9.00 am CEST / 10.00 am Israel time on Monday, 28 September 2026, as stated in the Notice. Include a scanned copy of any power of attorney or other authority under which the form is signed.

Corporate and joint shareholders. A corporate shareholder must execute this form under its common seal or have it signed on its behalf by an authorised officer or attorney. For joint holders, the appointment submitted by the most senior holder takes precedence; seniority is determined by the order of names in the register of members.

Changes and revocation. To change instructions, submit a new signed proxy form before the submission deadline. The latest valid appointment received before the deadline takes precedence. To revoke an appointment, send a signed written notice to the same email address by the deadline stated in the Notice, with any supporting authority.

Attendance. Returning this form does not prevent you from attending and voting at the AGM. If you attend and vote personally, your proxy appointment will terminate as described in the Notice. Videoconference access details will be provided by 29 September 2026. Contact the Company Secretary at the email address above for assistance.

Nominee holdings. If your shares are registered in the name of a nominee, broker or custodian, arrange voting instructions or an appropriate appointment through that intermediary. This form must be completed by the registered member or a person duly authorised to act for them.

Adjournment. This appointment also applies to any adjournment of the AGM. For the deadline applicable to an adjourned meeting, refer to the Notice and any further notification from the Company.

Notice and resolution numbering. Read this form together with the accompanying Notice. The Eutopos strategy is resolution 9; disapplication of pre-emption rights is resolution 10; capitalisation of reserves is resolution 11.

Registered office: 20–22 Wenlock Road, London, England, N1 7GU